Market Overview

UPDATE: Cantor Fitzgerald Raises PT to $13 on Synergy Pharmaceuticals on Positive Data

Related SGYP
1 Way To Search For The 'Next Big Thing' In Biotech
Benzinga's Top #PreMarket Gainers

Cantor Fitzgerald reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $13.

Cantor Fitzgerald commented, "Positive data announcement is a key catalyst: Synergy announced positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide. While details were not disclosed since the company is attempting to present late-breaker data at DDW, management indicated that (1) there was a nice dose response effect; and (2) the highest dose in the trial (3 mg) demonstrated a 19% responder rate versus 10.7% for placebo, which was statistically significant (p=0.009)."

Synergy Pharmaceuticals closed at $5.26 on Monday.

Latest Ratings for SGYP

DateFirmActionFromTo
Oct 2014Cantor FitzgeraldMaintainsBuy
Nov 2013Canaccord GenuityReiteratesBuy
Nov 2013Aegis CapitalReiteratesBuy

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (SGYP)

Around the Web, We're Loving...

Get Benzinga's Newsletters